MHF TOP PICKS FOR February
Every month, we at the Mueller Health Foundation like to showcase interesting news and updates in the field of tuberculosis (TB). Below are our top 3 picks for February:
- High-Dose Rifampin Shows No Benefit in TB Meningitis Trial
A recent randomized clinical trial found that giving adults with tuberculous meningitis a much higher dose of the antibiotic rifampin did not reduce deaths compared with standard therapy and may even have been associated with slightly worse mortality at six months. The study enrolled nearly 500 patients across Indonesia, Uganda, and South Africa and showed no survival advantage from high-dose rifampin, underscoring the need for new treatment strategies that better address the disease’s severe inflammatory response in the brain. To learn more, you can access the article here: https://www.cidrap.umn.edu/tuberculosis/high-dose-rifampin-fails-cut-tuberculous-meningitis-deaths-may-worsen-outcomes
- Large Global Study Reveals High Rates of TB Diagnostic Errors
A new study published in Nature Medicine estimates the scale of incorrect tuberculosis diagnoses in low- and middle-income countries by analyzing 2023 World Health Organization case-finding data from 111 countries. The researchers estimate that about 2.05 million people were falsely diagnosed with TB (false-positives) and roughly 1.00 million true TB cases were missed (false-negatives), suggesting that up to three in ten reported TB cases may be incorrect. While expanding rapid PCR-based diagnostic tools could significantly reduce underdiagnosis, the study indicates that substantial improvements in test sensitivity and reduced reliance on clinical judgment are needed to cut both false-negative and false-positive errors and strengthen global TB control efforts. To learn more, you can access the paper here: https://www.nature.com/articles/s41591-025-04097-5
DID YOU KNOW?
Indonesia is advancing the next phase of its national tuberculosis response based on an extensive August 2025 Joint Programme Review involving the Ministry of Health, WHO, and partners that assessed progress, identified systemic gaps, and laid out priorities for the forthcoming National TB Strategic Plan 2025–2029.
Despite high political commitment, the country’s TB burden remains large, with approximately 387 cases per 100,000 people and roughly 131,000 deaths in 2023 compared with earlier years, reflecting COVID-19 setbacks and persistent programmatic challenges.
The review combined field visits across multiple provinces with stakeholder interviews and data analysis to pinpoint actions needed to strengthen legal frameworks, secure sustainable financing, close detection and notification gaps, speed referrals, improve treatment success and retention, protect households from catastrophic costs, and tackle upstream risk factors like undernutrition, smoking, diabetes, and alcohol use.
Emphasis was also placed on empowering community health workers, integrating data systems, and galvanizing multi-sectoral action to identify and link one million people with TB to care and achieve a 90 % treatment success rate, while exploring TB vaccine introduction by 2028–2029.
These steps aim to translate evidence into implementation, bend the TB curve, and accelerate Indonesia’s progress toward its 2030 TB elimination targets.